The Parliamentary Under-Secretary of State for Health (Jane Ellison)
I congratulate my hon. Friend the Member for Salisbury (John Glen) on having secured a hat-trick of debates on the future of Porton Down, which is a very important subject not just for his constituents, but for the whole country, given the work done there on a wide range of public health threats, including the Ebola outbreak in west Africa. I join him in paying tribute to his constituents for their service both in the UK and on the frontline in Sierra Leone. The medals are hugely deserved.
My hon. Friend has been a tireless campaigner for his constituents on this matter and on the creation of Porton science park, which I will turn to later. Through this campaigning he has shown a passion for growth and job creation in his area, and we all admire that.
Scientists have been doing invaluable work at Porton Down since the 1950s. As my hon. Friend has said, in previous debates it has been stressed that the buildings are more than 60 years old and are increasingly becoming unfit for purpose. I know that my hon. Friend agrees with the need to find a solution to the problem—indeed, he devoted his speech to that—to ensure that the vital work can continue. It is important that scientists have the benefit of state-of-the-art facilities that reflect the latest technological advancements, including the shift from Petri dish to big data. So much has happened in recent years and so much change is going on. There is a clear consensus that the status quo is not acceptable and that it will not enable Public Health England to deliver the public health scientific expertise that the Government and the nation require.
My hon. Friend ran through the options. He knows that Public Health England has looked at a number of options to meet the challenge it faces. It has had to consider a wide range of longlisted and shortlisted options, all of which have to demonstrate the best value for money to the taxpayer. The main focus of the options has been on the existing Porton Down and Colindale sites, and the former GlaxoSmithKline facility in Harlow, Essex.
As my hon. Friend mentioned, Public Health England has briefed him and the local MPs, local authorities and other key stakeholders, and has consulted the chief medical officer and chief scientific officer, about the three sites affected and considered in the option appraisal. As my hon. Friend will be aware, PHE’s case is that there are significant benefits from bringing together the range of public health science functions that it manages at disparate sites. I accept that he expressed scepticism about some of the arguments, but PHE believes that creating an integrated national science hub rather than reproviding the same facilities on the same sites would be its ideal. For that reason, in the PHE outline business case, the preferred option was to create a public health science hub based at Harlow.
My hon. Friend asked what was included in some aspects of the outline business case. I can confirm that no additional revenues from any relocation have been included, in line with the rules and guidelines of what is and can be included in such cost-benefit analyses. However, it is hoped that new facilities will lead to increased academic and commercial income.
As I have said, it is essential that the proposal taken forward offers the best value for money for the taxpayer while protecting the vital heath protection functions carried out by scientists. The scrutiny of the business case has included two external reviews organised by the Major Projects Authority. Both have concluded that the business case properly evaluates the options, including options based at Porton. Since our last debate on this topic last September, the review process has continued and the business case has been through a Major Projects Authority gateway process. I can assure my hon. Friend that that has been and will continue to be a thorough and robust process, and that the outline business case continues to be scrutinised by Ministers at the Department of Health, the Treasury and the Cabinet Office.
As I have said, PHE has considered a wide range of options in the outline business case, including those that would involve remaining at Porton Down. Alternative, third-party proposals have been put forward, including those of the Porton life sciences group, which were kindly forwarded to me and to other Ministers by my hon. Friend. I assure him that the proposals have been carefully considered.
We recognise the need for collaboration between Public Health England and its neighbours at Porton and the Defence Science and Technology Laboratory, in the interests of national security. PHE is committed to being collaborative, including having discussions about the use of specialist high-containment facilities. However, we need to be clear that, although PHE and DSTL will continue to collaborate closely, PHE needs dedicated high-containment facilities to ensure that it can properly respond to the threat our nation faces. PHE is the employer of the specialists that are registered to handle human health specimens. The DSTL facilities provide additional resilience, but they were built to meet military requirements. In addition PHE’s facilities provide resilience to the military if DSTL’s facilities are for any reason unavailable. Whatever the final decision, national security, and capabilities for national response, are paramount. It is therefore key for DSTL and all other potential agencies involved in the response to work with PHE to protect public health from current and future threats.
Public Health England has confirmed that it remains committed to the Porton site, even if it is decided to relocate the Porton research functions and staff. That would involve the PHE facilities remaining at Porton consisting of some 300 staff in development and production and regional laboratories. That has continued, with PHE spinning out development and production as a corporate company called Porton Biopharma Ltd, which is wholly owned by the Secretary of State for Health. That will allow for Porton Biopharma Ltd to take a commercial approach to growing the business. I note my hon. Friend’s consistent support for that—he has not spoken against the idea. That allows more people across the world to benefit from the specialist products it manufactures. PHE has briefed my hon. Friend on that work and on maximising the commercial potential of the production facilities at Porton. As he said in his speech, that principle has his support.
The work to increase the commercial potential of the production facilities at Porton will be closely linked to the Porton science park, which I know my hon. Friend has worked hard to bring to his constituency. Porton Biopharma Ltd is next to the new science park and PHE is working closely with Wiltshire County Council on the further opportunities in the life sciences sector that this important development could bring to his constituency.
My hon. Friend rightly focused much of his remarks on the need to support staff in the most appropriate way, and on how unsettling it is for any group of staff to not quite know where their future lies. One third of the posts currently at Porton will remain there, even if research functions and staff are relocated. If those functions are relocated, PHE would work with each member of staff at Porton who is working in a post that would move to Harlow under the new proposals, to support them in decisions about their future. He is absolutely right to make that paramount and I take it very seriously. Some staff may want to relocate to Harlow and others may wish to retire or move to other roles outside PHE. The business case includes support packages for staff that are in line with the Government standard. I hope that gives him some reassurance.
As I have set out, the work conducted at Porton Down is of local, national and international importance. However, there is a consensus that, given the ageing facilities, doing nothing is not an option. PHE has looked at a wide range of possibilities for the future of health protection laboratories in the UK and at the benefits of combining various public heath functions. This has led to a preference for the Harlow site at the outline business case stage. Regardless of the final decision, PHE remains committed to the Porton site, as expressed through the commercialisation of its development and production arm. This will be closely linked to the Porton science park. The outline business case has been through, and continues to go through, rigorous, thorough and robust scrutiny before a final decision is reached by Ministers.
I thank my hon. Friend for his continued keen scrutiny of this important issue. I congratulate him once again on securing the debate and on continuing to be such an ardent champion for the interests of Porton as a science centre of excellence and for his constituents and their future.
Question put and agreed to.